Integrative CRISPR Activation and Small Molecule Inhibitor Screening for lncRNA Mediating BRAF Inhibitor Resistance in Melanoma.

Shamloo, Sama; Kloetgen, Andreas; Petroulia, Stavroula; Hockemeyer, Kathryn; Sievers, Sonja; Tsirigos, Aristotelis; Aifantis, Ioannis; Imig, Jochen

Shamloo, Sama; Kloetgen, Andreas; Petroulia, Stavroula; Hockemeyer, Kathryn; Sievers, Sonja; Tsirigos, Aristotelis; Aifantis, Ioannis; Imig, Jochen.

Afiliação

Shamloo S; Chemical Genomics Centre of the Max Planck Society, 44227 Dortmund, Germany.
Kloetgen A; Max Planck Institute of Molecular Physiology, 44227 Dortmund, Germany.
Petroulia S; Department of Pathology, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Hockemeyer K; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Sievers S; Chemical Genomics Centre of the Max Planck Society, 44227 Dortmund, Germany.
Tsirigos A; Max Planck Institute of Molecular Physiology, 44227 Dortmund, Germany.
Aifantis I; Department of Pathology, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Imig J; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.

Biomedicines ; 11(7)2023 Jul 21.

Article em En | MEDLINE | ID: mdl-37509693

Palavras-chave

CRISPR activation; drug resistance; lncRNA; melanoma; small molecule inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google